XML 69 R59.htm IDEA: XBRL DOCUMENT v3.25.3

Earnings per share (Tables)

12 Months Ended

Jun. 30, 2025

Disclosure [Abstract]

Summary of earnings per share

		2025 A$‘000				2024 A$‘000				2023 A$‘000
Earnings per share for losses from continuing operations
Loss after income tax attributable to the owners of Kazia Therapeutics Limited			(20,702	)			(26,778	)			(20,465	)
Loss after income tax attributable to the owners of Kazia Therapeutics Limited			(20,702	)			(26,778	)			(20,465	)
		Number				Number				Number
Weighted average number of ordinary shares used in calculating basic and diluted earnings per share			547,941,171				263,676,313				184,284,350
		Cents				Cents				Cents
Basic and diluted earnings per share			(3.78	)			(10.16	)			(11.23	)

X

- Definition

The disclosure of earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2025-01-01
-Paragraph 66
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_EarningsPerShareExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	kzia_DisclosureAbstract
Namespace Prefix:	kzia_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration